Koska, J., Migrino, R
Diabetes Care 48(1):S207-38 Marx N, Federici M, Schtt K, Mller-Wieland D, Ajjan RA, Antunes MJ et al (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)
10.1002/1878-0261.13685 69 KawaguchiT.YoshidaT.HaradaM.HisamotoT.NagaoY.IdeT.et al (2004)
Month 2 and beyond Building momentum Your personalized care plan evolves as you do
Description Orforglipron 6mg Oral GLP-1 Research Compound Orforglipron 6mg is a non-peptide oral GLP-1 receptor agonist research compound supplied in capsule format for laboratory and analytical research environments
( I ) cAMP levels in cell lysates were determined following pretreatment with 100 nM each of GLP-1(2836), scrambled control, or forskolin in siRNA-treated cells (white bars) versus the scrambled siRNA control (gray bars) ( n = 3/group for all cAMP and LDH assays, each in triplicate)